"This clinical study is a milestone event for Echo Therapeutics and we are extremely excited to begin recruitment of patients for enrollment in the trial. It is the final step before the submission of the CE Mark Technical File for potential market clearance and ensuing European commercial launch of Symphony," commented Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We look forward to providing updates in the near-term as we move toward our goal of making Symphony available to patients."
The clinical study is designed to evaluate the safety and efficacy of
the Symphony CGM System in a hospital setting. Glucose data will be
collected from thirty-two (32) critically ill patients at four U.S.
medical institutions. The Symphony CGM System glucose readings will be
paired with reference blood glucose measurements taken from a YSI 2300
STAT Plus Glucose Analyzer.